American Society of Clinical Oncology
ASCO 2021
This program was supported by Bayer Inc.
prostate cancer conference highlights
AUDIO & VIDEO CAPSULES
Moderated by Dr. Ricardo Rendon
Abstract Summaries
Dr. Steven Yip
- Abstract LBA4: Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).
/
RSS Feed
Watch video capsule
Abstract Summaries
Dr. Michael Ong
- Abstract 5000: A phase 3 trial with a 2×2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novometastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
- Abstract 5002: Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.
/
RSS Feed
Watch video capsule
Abstract Summaries
Dr. Claudio Jeldres
- Abstract 5072: Real-world first-line treatment patterns in patients with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.
/
RSS Feed
Watch video capsule
Abstract Summaries
Dr. Lucia Nappi
- Abstract 5020: Concordance of DNA damage repair (DDR) gene mutations in paired primary and metastatic prostate cancer (PC) samples.
/
RSS Feed
Watch video capsule
Abstract Summaries
Dr. Anupam Batra
- Abstract 5046: ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).
/
RSS Feed
Watch video capsule
The opinions expressed in these audio capsules are those of the physicians.